Skip to content

GINA 2026: asthma

International GINA Current

Global Strategy for Asthma Management and Prevention, 2026 update

Global Initiative for Asthma. 2026 Strategy Report
Summary checked against the source: 2026-11

Read or download the original

Covers adults and adolescents (12 years and over), with notes on children 6–11. Page numbers are the report's printed pages.

At a glance

  1. Diagnosis = typical variable symptoms + confirmed variable expiratory airflow (bronchodilator reversibility, PEF variability, response to ICS, or challenge test). [Box 1-2 · p. 28]
  2. No SABA-only treatment for adults and adolescents. Every patient should get ICS: the anti-inflammatory reliever (AIR) approach. [Box 4-6 · p. 83]
  3. Track 1 (preferred): as-needed low-dose ICS–formoterol as the reliever at every step, with maintenance-and-reliever therapy (MART) from step 3. [Box 4-6 · p. 83]
  4. Track 2: as-needed ICS–SABA (or SABA if unavailable), with maintenance ICS or ICS–LABA. [Box 4-6 · p. 83]
  5. Control: daytime symptoms or reliever >2×/week, any night waking, any activity limitation: 0 = well controlled, 1–2 partly, 3–4 uncontrolled. [Box 2-2 · p. 41]
  6. Exacerbation in ED: salbutamol (± ipratropium), oxygen to SpO₂ 92–95%, systemic corticosteroids, IV magnesium if severe. [Box 9-6 · p. 186]

Diagnosis

Criterion Adults Children 6–11
Variable symptoms Wheeze, breathlessness, chest tightness, cough; vary over time; worse at night or on waking; triggered by exercise, laughter, allergens, cold air; worse with viral infections Same
Bronchodilator reversibility (10–15 min after 200–400 µg salbutamol) FEV1 or FVC ↑ ≥12% and ≥200 mL (more confident if ≥15% and ≥400 mL); or PEF ↑ ≥20% FEV1 ↑ ≥12% predicted (or PEF ≥15%)
Diurnal PEF variability (twice daily for 2 weeks) >10% >13%
After 4 weeks of ICS FEV1 ↑ ≥12% and ≥200 mL (or PEF ≥20%) FEV1 ↑ ≥12% predicted
Bronchial challenge Methacholine: FEV1 ↓ ≥20%; hyperventilation, saline or mannitol ≥15%; exercise >10% and >200 mL Methacholine ≥20%; exercise >12% predicted
Between-visit variation FEV1 ≥12% and ≥200 mL FEV1 ≥12%

Adapted from GINA 2026 Box 1-2 [p. 28]

  • Withhold SABA ≥4 h and long-acting bronchodilators 24–48 h before reversibility testing.
  • Type 2 biomarkers (FeNO >50 ppb in adults, >35 in children; raised blood eosinophils) can support but not exclude asthma.

Assessment

In the past 4 weeks
Daytime symptoms more than twice a week?
Any night waking due to asthma?
SABA reliever more than twice a week? (not ICS–formoterol, not pre-exercise)
Any activity limitation due to asthma?
None = well controlled · 1–2 = partly controlled · 3–4 = uncontrolled

Adapted from GINA 2026 Box 2-2 [p. 41]

Risk factors for exacerbations even with few symptoms: high SABA use (≥3 canisters/year; ≥1 a month raises mortality), inadequate ICS, obesity, chronic rhinosinusitis, GERD, food allergy, pregnancy, smoking or e-cigarettes, allergen or pollution exposure, psychosocial problems, FEV1 <60%, high bronchodilator responsiveness, raised eosinophils or FeNO, ever intubated or in ICU, ≥1 severe exacerbation in the last year. [Box 2-2 · p. 41]

Measure FEV1 at the start, after 3–6 months of ICS (personal best), then periodically. [p. 41]

Treatment: adults and adolescents

Step Track 1 (preferred): reliever = as-needed low-dose ICS–formoterol Track 2 (alternative): reliever = as-needed ICS–SABA (or SABA)
1 AIR-only: as-needed low-dose ICS–formoterol AIR-only: as-needed low-dose ICS + SABA
2 AIR-only (as step 1) Low-dose maintenance ICS
3 MART with low-dose ICS–formoterol Low-dose maintenance ICS–LABA
4 MART with medium-dose ICS–formoterol Medium-dose maintenance ICS–LABA
5 Add-on LAMA; refer for phenotyping; consider a trial of high-dose maintenance ICS–formoterol; biologics: anti-IgE, anti-IL5/5R, anti-IL4Rα, anti-TSLP Add-on LAMA; refer; consider high-dose ICS–LABA; same biologics

Adapted from GINA 2026 Box 4-6 [p. 83]

Why Track 1: using ICS–formoterol as the reliever cuts exacerbations compared with a SABA reliever, and it's a simple single-inhaler strategy. Before choosing Track 2, check the patient will take their maintenance ICS. Maintenance OCS only as a last resort. [p. 83]

Personalised cycle: assess, adjust, review

Assess: diagnosis, symptom control and risk factors, comorbidities, inhaler technique and adherence, goals. Adjust: treat risk factors and comorbidities, non-drug strategies, medication, education and a written action plan. Review: symptoms, exacerbations, side effects, lung function, satisfaction. [Box 4-6 · p. 83]

Inhaled corticosteroid doses (adults and adolescents, µg/day)

ICS Low Medium High
Beclometasone (pMDI, standard particle) 200–500 >500–1000 >1000
Beclometasone (DPI or extrafine pMDI) 100–200 >200–400 >400
Budesonide (DPI or pMDI) 200–400 >400–800 >800
Ciclesonide 80–160 >160–320 >320
Fluticasone furoate (DPI) 100 200
Fluticasone propionate 100–250 >250–500 >500
Mometasone furoate (pMDI) 200–400 >400

Not a table of equivalence: switching products at the "same" level may change potency. Most of the benefit of ICS comes from low doses. Adapted from GINA 2026 Box 4-2 [p. 77]

Acute asthma in the emergency department

flowchart TD
    A["Adult, adolescent or child ≥6 with acute asthma<br/>Exclude other causes: pneumothorax, anaphylaxis, ILO,<br/>pneumonia, heart failure, PE"] --> L{"Life-threatening?<br/>drowsy, confused, cyanosed, silent chest"}
    L -->|Yes| LT["Nebulised salbutamol + ipratropium, oxygen,<br/>systemic steroids (IM adrenaline if anaphylaxis)<br/>Call PICU or anaesthesia · IV access · IV magnesium<br/>CXR, blood gases, monitor continuously"]
    L -->|No| S{"Severity"}
    S --> MI["Mild: talks in sentences, SpO₂ ≥94%,<br/>PEF or FEV1 &gt;70%<br/>Salbutamol 4 puffs by pMDI + spacer, or<br/>budesonide–formoterol 160/4.5 × 2; repeat after 30–60 min if needed"]
    S --> MO["Moderate: phrases, accessory muscles,<br/>SpO₂ ≥92%, PEF 50–70%<br/>Salbutamol 4–6 puffs + ipratropium 4 puffs (up to ×3, 20–30 min apart)<br/>Systemic corticosteroids"]
    S --> SE["Severe: can't speak, SpO₂ &lt;92%, RR &gt;30,<br/>silent chest, PEF &lt;50%<br/>Salbutamol 6–10 puffs + ipratropium (or 5 mg + 0.25 mg nebulised, ×3)<br/>O₂ to SpO₂ 92–95%, systemic steroids, consider IV magnesium"]
    MI --> R["Review at 1 hour"]
    MO --> R
    SE --> R
    R -->|"Marked improvement"| D["Discharge if SpO₂ ≥92%, PEF &gt;70%,<br/>stable 1–2 h after last salbutamol"]
    R -->|"Partial improvement"| P["Continue, extra SABA and ipratropium,<br/>steroids if not started; review hourly"]
    R -->|"Worsening"| W["Extra bronchodilators, IV magnesium,<br/>consider PICU/ICU"]
    P --> H["Admit if SpO₂ &lt;92%, SABA needed<br/>more than every 1–2 h, or still breathless<br/>4–6 h after steroids"]
Adapted from GINA 2026 Box 9-6 [p. 186]

  • Red flags for fatal or near-fatal asthma: previous intubation for asthma; admission or several ED visits in the past year; current or recent OCS; not using ICS; poor adherence or no action plan; more than one salbutamol canister a month or nebulised SABA; psychiatric or psychosocial problems; food allergy or anaphylaxis; poor perception of airflow limitation. [Box 9-1 · p. 172]
  • After an exacerbation: switch SABA users to MART with ICS–formoterol (or medium-dose ICS–LABA for 2–4 weeks); continue any increased ICS for 2–4 weeks and never stop it; check inhaler technique and adherence; written action plan; early follow-up. [p. 171, 190]

Clinical pearls

  • Reversibility ≥12% and ≥200 mL in FEV1. Methacholine: ≥20% fall.
  • No SABA-only therapy in adults and adolescents; ICS–formoterol as reliever (Track 1).
  • Control = 4 questions about the last 4 weeks.
  • Life-threatening signs: silent chest, cyanosis, confusion, drowsiness. Rising or normal PaCO₂ is ominous.
  • IV magnesium for severe attacks not responding to initial treatment.

Classes and levels of evidence

How GINA 2026 grades its recommendations. Adapted from GINA 2026 evidence levels [full report]. Hover over any class or level cited on this page to see what it means.

Evidence level Meaning
A Randomised controlled trials, systematic reviews and meta-analyses; rich body of data
B Randomised controlled trials and meta-analyses; limited body of data
C Non-randomised trials or observational studies
D Panel consensus judgement

GINA is a strategy report. Its key recommendations carry an evidence level from A to D (shown in the report as "Evidence A" and so on), but most boxes summarised here don't, so citations on this page give the report page.